Formulation Development
Vaccinex Announces Multiple New Agreements for Access to ActivMAb Antigen Virus Technology
Vaccinex, Inc. recently announced it has entered into eight new antibody discovery agreements integrating use of its proprietary ActivMAb platform to select antibodies against difficult-to-drug…
XOMA Enters Agreement to Acquire Kinnate Biopharma
Upon closing, XOMA anticipates adding approximately $9.5 million in cash to its balance sheet and several early-stage programs to potentially add to its royalty portfolio….
Voyager Therapeutics Reports Robust Preclinical Activity in Tau Silencing Gene Therapy Program for Alzheimer’s Disease; Advances Program Into Late Research
Voyager Therapeutics, Inc. recently announced new data from its two preclinical programs targeting pathological tau for the treatment of Alzheimer’s disease. Data on VY-TAU01, Voyager’s…
Evonik Partners With University of Mainz to Commercialize New Class of PEG Lipids for Nucleic Acid Delivery
Evonik and the University of Mainz have signed a license agreement to commercialize randomized polyethylene glycols (rPEGs), a new class of PEGs. Evonik intends to use….
Monopar Receives Clearance to Proceed With First-in-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced Cancers
Monopar Therapeutics Inc. recently announced it has received Human Research Ethics Committee (HREC) clearance in Australia to commence a Phase 1 dosimetry trial of its…
Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer
Immuneering Corporation recently announced the US FDA granted Fast Track designation for its lead clinical-stage program, IMM-1-104, for the treatment of patients with pancreatic ductal…
Mestag Therapeutics Enlists Leading Cancer Biology & Immunology Advisors to Support Clinical Development of its Lead Oncology Program
Mestag Therapeutics recently announced the appointments of additional distinguished, world-leading advisors to guide the development of its lead program M300, a first-in-class antibody program designed…
OrphAI Therapeutics Receives Orphan Drug Designation for AIT-101 as a Treatment for Amyotrophic Lateral Sclerosis in the European Union
OrphAI Therapeutics Inc. recently announced it has received Orphan Drug Designation (ODD) in the European Union (EU) for the treatment of amyotrophic lateral sclerosis (ALS).…
Alvotech Announces Expected Global Market Entry Dates for Biosimilar to Stelara
Alvotech recently announced it has reached settlement agreements with Johnson & Johnson in Japan, Canada, and in the European Economic Area (EEA) for AVT04, a…
Vaxxinity’s Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data Published
Preclinical data published in the Journal of Lipid Research indicate VXX-401 is well-tolerated, with no safety signals observed, and robustly reduces LDL-C in cynomolgus monkeys…..
PathAI Announces Exclusive Collaboration With Roche Tissue Diagnostics to Advance AI-enabled Interpretation for Companion Diagnostics
PathAI, Inc. recently announced an expanded and exclusive relationship with Roche Tissue Diagnostics (RTD) that will bring AI-enabled interpretation to companion diagnostics. Building upon the success…
VantAI Enters $674-Million Collaboration With Bristol Myers Squibb to Accelerate Molecular Glue Drug Discovery Through Artificial Intelligence
Collaboration to leverage VantAI’s expertise in generative AI and geometric deep learning to identify molecular glues against targets of interest with an option to expand to additional programs….
TILT Biotherapeutics Awarded Grant from US Department of Defense for Ovarian Cancer Immunotherapy Research
TILT Biotherapeutics recently announced it has been selected by the US Department of Defense (DOD), America’s largest government agency, to receive a $2-million grant for…
Silo Pharma’s Ketamine Implant Demonstrates Successful Drug Delivery
Silo Pharma, Inc. recently provided a positive update on SP-26, its novel time-released, dose-controlled formulation of ketamine initially targeted for fibromyalgia. A preclinical research study…
Vetter Contributes to Commercial Launches of Eight Customer Products in 2023
New molecules candidates brought to Vetter in the clinic receive strategic counsel and experienced support to guide their path to market and beyond….
Study Demonstrates the Potential of HelixBind’s RaPID/BSI Assay to Accurately Identify Bloodstream Infections Associated With Sepsis in Patients Undergoing Antimicrobial Treatment
HelixBind, Inc. recently announced the publication of a peer-reviewed study demonstrating the capability of the company’s RaPID/BSI assay to accurately identify bloodstream infections associated with…
NovelMed's Ruxoprubart Receives FDA Orphan Drug Designation for Paroxysmal Nocturnal Hemoglobinuria Treatment
NovelMed recently announced the US FDA has granted Orphan Drug Designation (ODD) to Ruxoprubart, an alternative pathway (AP) blocker anti-Bb antibody, for the treatment of…
Abzena Launches LabZient™, an Analytical Platform to Expedite the Path to IND for Antibodies
Abzena recently announced the launch of its new analytical platform, LabZient™. The standardized and automated platform streamlines the assessment and validation of large molecules, which significantly….
CDMO Alcami Expands Fill/Finish Manufacturing Capacity With New Charleston Line
Alcami Corporation recently announced the strategic expansion of its sterile fill/finish manufacturing capacity with the addition of a new sterile fill/finish line with isolator and two lyophilizers at….
WHITEPAPER - Revolutionizing Small Molecule API Production: Unveiling the Impact of Fermentation as a Sustainable Solution
While large molecules continue to advance in drug development pipelines, small molecule Active Pharmaceutical Ingredients (APIs) still retain their historical dominance among new drug applications…
